BeiGene’s Brukinsa Approved by FDA for Chronic Lymphocytic Leukemia
China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the US FDA has...
Company
Dartsbio Pharmaceuticals Secures RMB 100 Million in Series B Financing
Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has reportedly raised over RMB 100 million in a...
CNBG-Virogin’s Omicron-Targeted mRNA Vaccine Approved for Clinical Trials
CNBG-Virogin Biotech (Shanghai) Co., Ltd has announced obtaining clinical trial approval from the National Medical...
Hepagene’s FXR Agonist HPG1860 Shows Positive Phase IIa Data in NASH Study
China-based liver disease specialist Hepagene Therapeutics (HK) Limited has revealed positive data from the Phase...
Ascentage Pharma Raises HKD 550 Million in Secondary Offering for Pipeline Expansion
Suzhou-based Ascentage Pharma (HKG: 6855) is set to conduct a secondary offering of 22.5 million...
BMS’s Opdivo Approved in China for Neoadjuvant Therapy in Urothelial Carcinoma
US-based Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another new indication approval in China for...
Harbour BioMed Receives FDA Approval for HBM1007 Clinical Study
China-based Harbour BioMed (HKG: 2142) has announced receiving approval from the US FDA to initiate...
Joincare’s Biosimilar Tocilizumab Approved for Marketing in China
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that its subsidiary Zhuhai...
CANbridge Pharmaceuticals Initiates Phase II Dosing for CAN103 in Gaucher Disease
China-based CANbridge Pharmaceuticals, Inc. (HKG: 1228) has announced the first patient dosing in the Phase...
GenScript ProBio Closes $220M Series C Financing for Biologics and Gene Therapy Expansion
Contract Development and Manufacturing Organization (CDMO) GenScript ProBio has announced the completion of a $220...
Roche and HKSTP Collaborate to Boost Life Sciences in Greater Bay Area
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a multi-faceted collaboration agreement with the Hong...
Burning Rock Upgrades 2022 Revenue Growth Forecast to 10% YOY
Guangzhou-based medical device giant Burning Rock Ltd (NASDAQ: BNR) has issued a notice upgrading its...
Pasithea Therapeutics Partners with WuXi AppTec for API Manufacturing of PAS-004
US-based Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced that Chinese Contract Research Organization (CRO) WuXi...
CDE Grants Priority Review to Takeda’s Vonicog Alfa, Zhongmei’s Rilonacept, and Zai Lab’s SUL-DUR
The Center for Drug Evaluation (CDE) has indicated that Takeda’s Vonicog alfa, Zhongmei Huadong Pharma’s...
Immunofoco’s CLDN18.2-Targeted CAR-T Therapy IMC002 Accepted for CDE Review
China’s Center for Drug Evaluation (CDE) has accepted a clinical trial filing for IMC002, an...
Keymed Biosciences’ CMG901 Shows Promising Results in Phase Ia Study for Solid Tumors
China-based Keymed Biosciences Inc. (HKG: 2162) has revealed the latest data update from a Phase...
MDHC Group Raises Hundreds of Millions in Third Financing Round
Jiangsu-based MDHC Life Technologies (Kunshan) Co.,Ltd, a leading platform in minimally invasive surgery and life...
Staidson’s STSP-0601 Begins Phase II Study for Hemophilia Treatment
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced the first subject dosing in...
Everest Medicines’ EVER206 Shows Positive Phase I Results in China
China-based Everest Medicines (HKG: 1952) has announced top-line results from a Phase I study in...
Bliss Bio Raises RMB 100 Million in Series B+ Financing for Oncology Pipeline
Hangzhou-based oncology-focused clinical-stage biotech Bliss Bio has reportedly raised over RMB 100 million (USD 14.7...